company
Ajanta Pharma Ltd.
Jurisdiction: US
FDA Warning Letter timeline
V1 scope: FDA Warning Letters only. Additional public-record sources (SEC, CPSC, federal contracts) are on the V2 roadmap and are not surfaced here today.
- fda_recall · drug_recall2026-05-13Ajanta Pharma Ltd. — Class II recall: Duloxetine Delayed-Release Capsules, 20 mg, Rx Only, 60 capsules, Marketed by: A…
- fda_recall · drug_recall2026-05-13Ajanta Pharma Ltd. — Class II recall: Duloxetine Delayed-Release Capsules, 30 mg, Rx Only, a) 90 Capsules, NDC 27241-0…
- fda_recall · drug_recall2026-05-13Ajanta Pharma Ltd. — Class II recall: Duloxetine Delayed-Release Capsules, 60 mg, Rx Only, 30 capsules, Marketed by: A…
Frequently asked questions
- How many FDA warning letters has Ajanta Pharma Ltd. received?
- Argus HQ has not recorded an FDA warning letter for Ajanta Pharma Ltd. in our current dataset.
- What FDA recalls has Ajanta Pharma Ltd. issued?
- Argus HQ has recorded 3 FDA recalls tied to Ajanta Pharma Ltd..
- Is Ajanta Pharma Ltd. FDA compliant?
- Argus HQ is not a compliance rating service. As of this page's last update, our dataset shows 0 warning letters, 3 recalls, and 0 approval records for Ajanta Pharma Ltd.. Review the linked FDA source records directly before drawing a compliance conclusion.
Informational only. FDA Warning Letters are public records (17 USC §105). Summaries are AI-assisted and may contain errors; always verify against the original FDA letter before acting. Not legal, financial, or regulatory advice.